返回
Presence of myositis-specific autoantibodies may predict favourable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study
10.1093/mr/roaf097
2025-11-01
0
PRE
AI
摘要
En 中文
Objective This study aimed to evaluate the autoantibody profile, including myositis-associated autoantibodies (MAAs) and myositis-specific autoantibodies (MSAs), and their influence on outcomes of rituximab (RTX) treatment in patients with IIM.Methods This retrospective observational study included data from patients with idiopathic inflammatory myositis (IIM) who met at least one of the following criteria: Bohan and Peter, ACR/EULAR 2017, and European Neuromuscular Center (ENMC) criteria.Results Fifty-three patients, 72% of whom were female, were included. Among them, 32.1% had a clinical diagnosis of dermatomyositis, 35.8% antisynthetase syndrome (ASS), 15.3% overlap syndrome, 11.3% polymyositis, and 5.7% had immune-mediated necrotizing myopathy. RTX was used in 49% of the patients, and nearly half of them (46%) had ASS. Remission was achieved in 77%, a partial response was observed in 11.5%, and unresponsiveness/active disease was observed in 11.5% of patients receiving RTX. Relapse was lower, and mortality tended to be lower in patients receiving RTX. In multivariate analysis, MSA positivity was associated with remission in those receiving RTX.Conclusions In our study, RTX was safe and effective in patients with IIM who had an inadequate response or severe disease at admission. Furthermore, the presence of MSAs may predict a favourable response to RTX treatment in patients with IIM.
关键词:
Anti-synthetase syndrome
idiopathic inflammatory myositis
myositis-associated antibodies
rituximab
myositis-specific antibodies
期刊
M
IF:
1.9
论文数: 52
・
被引数: 4.2K
学者
E
Emin Oğuz
H 指数:
0
论文数: 2
・
被引数: 0
N
Nevzat KOCA
H 指数:
0
论文数: 3
・
被引数: 0
M
Murat Bektaş
H 指数:
8
论文数: 106
・
被引数: 213
机构
I
Istinye University
学者数:
1.1K
论文数: 1.3K
・
被引数: 1.9K
引用论文